SAB BIOTHERAPEUTICS INC Stock Price, News & Analysis

SAB Biotherapeutics (Nasdaq: SABS) announced that Dr. Alexandra Kropotova will present at the Biotech Showcase in San Francisco on Jan. 10, 2023. Her presentation will focus on SAB's innovative DiversitAb™ platform, which develops fully-human polyclonal antibodies using transchromosomic cows, offering potential treatments for complex diseases like influenza and type 1 diabetes. The company emphasizes its commitment to addressing multiple disease targets simultaneously, showcasing promising data from clinical trials that indicate long-lasting efficacy against various pathogens.

SAB Biotherapeutics (SABS) announced promising results from a collaboration with CSL, confirming that its DiversitAb™ platform can produce fully-human anti-idiotype polyclonal antibodies. These findings demonstrated the potential to target and neutralize autoantibodies linked to autoimmune diseases, such as neuromyelitis optica. The platform effectively developed treatments that bind to harmful autoantibodies without broad immunosuppression, indicating significant therapeutic implications for various autoimmune disorders. SAB aims to provide effective treatment options for patients affected by these diseases.

SAB Biotherapeutics (Nasdaq: SABS, SABSW) has been chosen to present at the Biotech Showcase 2023 from January 9-11 in San Francisco. Dr. Alexandra Kropotova will deliver a presentation on January 10, focusing on the company's unique DiversitAb™ platform, which generates fully-human polyclonal antibodies without human donors. This platform shows promise against various pathogens, including influenza and Clostridioides difficile. The conference will also facilitate networking opportunities with potential partners and investors.

SAB Biotherapeutics has announced a successful private placement, raising approximately $7.9 million by selling around 7.3 million shares of common stock and warrants. This transaction, which closed on December 7, 2022, attracted existing and new institutional investors, including noted biotech investor T. Denny Sanford. The warrants, priced at $1.08, will be exercisable in six months and expire in five years. Funds raised will support SAB's immunotherapy pipeline targeting Clostridioides difficile and type 1 diabetes, along with general corporate purposes.

SAB Biotherapeutics (Nasdaq: SABS) reported its Q3 2022 financial results, highlighting developments in its immunotherapy pipeline. The company secured $8.6 million from its DoD contract and expects operational funding to last until July 2023. However, cash reserves fell to $8.3 million from $16.6 million, due to a $7.1 million operating loss. R&D expenses decreased to $7.4 million compared to $15.1 million last year. The net loss was $7.1 million, consistent with the previous year's loss of $4.1 million. SAB plans to advance its anti-influenza and C. diff therapeutic candidates significantly.

SAB Biotherapeutics (SABS) will present at the U.S. Pharma Partnering Summit on Nov. 17-18, 2022, in Boston, MA. Co-Founder and CEO Eddie Sullivan will discuss the company's DiversitAb™ platform and its promising therapeutics, including SAB-176 for influenza, SAB-195 for C. diff, and SAB-185 for COVID-19, during the presentation titled “Novel Biologic Therapeutics for Infectious Diseases.” The summit aims to enhance networking and deal-making within the biopharmaceutical industry, aligning with SAB's goals for innovation in immunotherapy.

SAB Biotherapeutics presented data on its polyclonal antibodies, SAB-176 for influenza and SAB-185 for COVID-19, demonstrating significant efficacy against highly mutating viruses at the 2022 Plasma Product Biotechnology Conference. The DiversitAb™ platform allows production of human antibodies without needing blood donations, enhancing safety and potency. Phase 2 results indicate SAB-185 effectively neutralizes multiple SARS-CoV-2 variants, while SAB-176 significantly reduced viral loads in H1N1 challenged adults, supporting its potential in treating respiratory diseases.

SAB Biotherapeutics (SABS) has entered an exclusive manufacturing services agreement with Emergent BioSolutions (EBS) to support the production of their fully-human polyclonal antibody products. This collaboration enables SAB to focus on R&D while Emergent provides end-to-end cGMP manufacturing services. SAB's immunotherapy platform utilizes transchromosomic cows to create targeted, high-potency antibodies for various diseases, including influenza and C. diff. The financial terms of the agreement were not disclosed, but it marks a strategic advancement for SAB's clinical programs.

SAB Biotherapeutics (Nasdaq: SABS) announced significant findings from its polyclonal antibody platform at the OPTIONS XI conference in Belfast. New data revealed that SAB-176 effectively reduced H1N1 viral load and improved symptoms in a Phase 2a trial. Additionally, the SAB-185 candidate demonstrated efficacy against various SARS-CoV-2 variants. Both therapeutic candidates showcased the platform's ability to neutralize rapidly mutating viruses, reinforcing SAB's innovative position in immunotherapy.